Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | AGXT | P21549 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136626 | 0.96 | APLNR (0.37) | APLNRP2RX4IDO1AGXTTLR9 | |
| SCHEMBL1097291 | 0.89 | BCHE (0.36) | CA1CA2 | |
| SCHEMBL135297 | 0.89 | APLNR (0.34) | APLNRCA1CA2 | |
| SCHEMBL14511262 | 0.84 | APLNR (0.36) | APLNRP2RX4IDO1AGXTTLR9 | |
| SCHEMBL136625 | 0.84 | APLNR (0.36) | APLNRP2RX4IDO1AGXTTLR9 | |
| SCHEMBL1096195 | 0.80 | BCHE (0.39) | — | |
| SCHEMBL1096197 | 0.80 | BCHE (0.39) | — | |
| SCHEMBL1097346 | 0.80 | BCHE (0.39) | — | |
| SCHEMBL130438 | 0.80 | APLNR (0.33) | APLNR | |
| SCHEMBL1097290 | 0.78 | BCHE (0.36) | IDO1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464106-B2 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2016-10-11 | — | — | US | disclosed |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | EXIQON A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-1446412-B1 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON AS (DK) | 2012-03-07 | — | — | EP | disclosed |
| US-20070117144-A1 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2007-05-24 | — | — | US | disclosed |
| US-20040219565-A1 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2004-11-04 | — | — | US | disclosed |
| EP-1446412-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | Exiqon A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20030224377-A1 | Novel LNA compositions and uses thereof | QIAGEN GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| WO-2003020739-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON A/S (DK) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219565-A1 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | UPF1, DCLRE1B, SNRPA1 | APLNR 704/4885P2RX4 4469/4885IDO1 4824/4885 |
| US-20030224377-A1 | Novel LNA compositions and uses thereof | RNGTT, NCL, NSUN2 | APLNR 1353/4885P2RX4 3978/4885IDO1 4730/4885 |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | UPF1, DCLRE1B, SNRPA1 | APLNR 704/4885P2RX4 4469/4885IDO1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.